source
- BioNTech's HER2-directed ADC shows modest benefit and higher lung toxicity in phase 3 trialBioNTech reported results of its phase 3 DYNASTY-Breast02 trial evaluating trastuzumab pamirtecan (t-pam), an HER2-directed antibody-drug conjugate, in patients with HR-positive, HER2-low metastati…
- FDA Commissioner Highlights New Rare Disease Framework Emphasizing Patient VoiceActing US Food and Drug Administration (FDA) Commissioner Kyle Diamantas highlighted the agency's new rare disease framework during a fireside chat at the NORD Breakthrough Summit. The framework i…